Status:
COMPLETED
Embryo Selection by Noninvasive Preimplantation Genetic Test
Lead Sponsor:
Peking University Third Hospital
Collaborating Sponsors:
Jinling Hospital, China
Reproductive Medical Center of Hebei Maternity Hospital
Conditions:
Infertility
Chromosome Abnormality
Eligibility:
FEMALE
35-42 years
Phase:
NA
Brief Summary
The objective of this study is to explore whether non-invasive chromosome screening (NICS) can be used as an effective indicator for embryos selection besides morphology through a multicenter randomiz...
Detailed Description
Chromosomal abnormalities commonly exist in early human embryos, and often cause embryo implantation failure and pregnancy loss in in-vitro fertilization (IVF) treatments. Preimplantation genetic test...
Eligibility Criteria
Inclusion
- Infertile couples receiving IVF- ICSI procedure for assisted reproduction cycle
- Female age: 35 - 42 years old
- Women receiving controlled ovarian hyperstimulation treatment (including ultra-long protocol、long-protocol 、short protocol treatment with GnRH agonist and GnRH antagonist treatment protocol); and the number of oocytes ≥6; The female BMI is from 18 to 30kg/m2.
- Culture embryos to blastocyst stage and all the blastocysts will be single cryopreserved.
- Single frozen-thawed blastocyst Transferred for the first time
- The number of blastocysts ≥2, morphology grade (above 4BC/4CB)
- Written informed consent
Exclusion
- One of couples with IVF or ICSI contraindications(such as poorly controlled type I or type II diabetes; liver disease or dysfunction; kidney disease or renal function abnormality; significant anemia; history of deep venous thrombosis, pulmonary embolus; history of cerebrovascular accident; uncontrolled hypertension or diagnosed heart disease; history of cervical, endometrial or breast cancer; undiagnosed vaginal bleeding.)
- PGT cycles
- Women who have pathologies or malformations that affect the pregnancy outcome: genital malformations, untreated hydrosalpinx, untreated uterine infections, intramural myomas \> 4cm , benign tumor of pelvic and abdominal cavity\> 4cm, intimal thickness\<8mm, pituitary tumors and malignant tumors of various tissues and organs during the patient's participation in the study
- Untreated hyperprolactinemia, thyroid disease, adrenal disease
- Women with endometrial polyps that were not treated before embryo transfer
Key Trial Info
Start Date :
April 16 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 6 2024
Estimated Enrollment :
1152 Patients enrolled
Trial Details
Trial ID
NCT04339166
Start Date
April 16 2020
End Date
August 6 2024
Last Update
December 11 2025
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital,Sun Yat-sen University
Guanzhou, Guangdong, China
2
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China
3
Hebei Maternity and Reproductive hospital
Shijiazhuang, Hebei, China
4
The Second Hospital of Hebei Medical University
Shijiazhuang, Hebei, China